Supreme Court Seems Unconvinced USPTO Should Receive Attorneys' Fees In District Court Litigation
Executive Summary
Justices question why it took 170 years for the patent office to seek attorneys' fees from patent applicants who challenge its decisions in district court; USPTO acknowledges the delay is 'atmospherically unhelpful.'
You may also be interested in...
US ‘Blocking-Patent’ Doctrine Comes Under Attack
A US court doctrine that has invalidated patents covering major drugs such as Ampyra and Restasis is under attack from petitions to the US Supreme Court filed by Acorda and Allergan.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.